Shared decision-making in the context of COVID-19
Conclusion: So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.
Source: Revista Brasileira de Terapia Intensiva - Category: Intensive Care Source Type: research
More News: Actemra | Azithromycin | Brazil Health | Clinical Trials | Corticosteroid Therapy | COVID-19 | Hydroxychloroquine | Infectious Diseases | Influenza | Intensive Care | Kaletra | Norvir | Oseltamivir | Tamiflu | Zithromax